Table 6 TUNA vs. other minimally invasive therapies. Efficacy
Variable | No. studies (patients) | TUNA Difference in means (% improvement) | TUMT Difference in means(% improvement) | TUNA vs. TUMT WMD (95% CI), P value |
|---|---|---|---|---|
Symptom score | ||||
Pre-3 months | 156 (76) | -9.3 (48%) | -5.2 (28%) | -4.1 (-5.02, -3.18), .00 |
Quality-of-life score | ||||
Pre-3 months | 156 (76) | -2.3 (49%) | -1.7 (39%) | -0.6 (-0.75, -0.44), .00 |
Qmax (mL/s) | ||||
Pre- 3 months | 156 (76) | 1 (11%) | 0.9 (12%) | 0.1 (-0.47, 0.67), .73 |
Variable | No. studies (patients) | TUNA Difference in means (% improvement) | WIT Difference in means (% improvement) | TUNA vs. WIT WMD (95% CI), P value |
Qmax (ml/sec | ||||
Pre- 6 months | 158 (37) | 3.2 (41%) | 1.8 (14%) | 1.4 (-0.13, 2.93), .07 |
Pre- 2 years | 158 (37) | 4.9 (44%) | 2.2 (18%) | 2.7 (1.14, 4.26), .00 |
PVR (mL) | ||||
Pre- 6 months | 158 (37) | -58.3 (62%) | -18.5 (25%) | -39.8 (-46.4, -33.2), .00 |
Pre- 2 years | 158 (37) | -40.9 (54%) | -23.3 (49%) | -17.6 (-24, -11.2), .00 |
P det at Qmax (cm H 2 O) | ||||
Pre- 6 months | 158 (37) | -22.52 (35%) | -17.5 (27%) | -5.02 (-9.36, -0.65), .02 |
Pre- 2 years | 158 (37) | -28.56 (44%) | -15.7 (25%) | -12.9 (-17.4, -8.34), .00 |
Variable | No. studies (patients) | TUNA Difference in means (% improvement) | ILC Difference in means (% improvement) | TUNA vs. ILC WMD (95% CI), P value |
Symptom score | ||||
Pre- 3 months | 156 (84) | -9.3 (48%) | -12.4 (64%) | 3.1 (2.36, 3.84), .00 |
Quality-of-life score | ||||
Pre- 3 months | 156 (84) | -2.3 (49%) | -2.5 (58%) | 0.2 (0.06, 0.34), .00 |
Qmax (mL/s) | ||||
Pre- 3 months | 156 (84) | 1 (11%) | 5 (53%) | -4 (-4.64, -3.36), .00 |
Pre- 6 months | 158 (95) | 3.2 (41%) | 2.8 (30%) | 0.4 (-0.15, 0.95), .15 |
Pre- 2 years | 158 (95) | 4.9 (44%) | 3 (32%) | 1.9 (1.27,2.52), .00 |
PVR (mL) | ||||
Pre- 3 months | 156 (84) | -22.1 (26%) | -71.9 (72%) | 49.8 (41.99, 57.60), .00 |
Pre- 6 months | 158 (95) | -58 (62%) | -45 (45%) | -13 (-16.41, -10.2), .00 |
Pre- 2 years | 158 (95) | -41 (54%) | -42 (42%) | 1.3 (-2.07, 4.67), .45 |
P det at Qmax (cm H 2 O) | ||||
Pre- 6 months | 158 (95) | -22.5 (35%) | -25.8 (38%) | 3.28 (1.4, 5.16), .00 |
Pre- 2 years | 158 (95) | -28.6 (44%) | -23 (34%) | -5.56 (-7.76, -3.36), .00 |
Variable | No. studies (patients) | TUNA Difference in means (% improvement) | TUVP Difference in means (% improvement) | TUNA vs. TUVP WMD (95% CI), P value |
Symptom score | ||||
Pre- 6 months | 157 (32) | -9 (47%) | -13.1 (69%) | 4.1 (2.38, 5.82), .00 |
Pre-1 year | 157 (32) | -11.2 (58%) | -13.3 (70%) | 2.1 (0.72, 3.48), .00 |
Pre- 2 years | 157 (32) | -10 (52%) | -12.7 (66%) | 2.7 (1.13, 4.27), .00 |
Qmax (mL/s) | ||||
Pre- 6 months | 257,58 (69)a | 3.42 (41%) | 10.25 (108%) | -6.08 (-8.6, -3.5), .00 |
Pre- 1 year | 157 (32) | 2.6 (30%) | 12.4 (132%) | -9.8 (-10.97, -8.63), .00 |
Pre- 2 years | 257,58(69)b | 2.76 (44%) | 8.93 (97%) | -6.1 (-11.45, -0.67), .00 |
PVR (mL) | ||||
Pre- 6 months | 257,58 (69)c | -57.26 (62%) | -61.84 (76%) | 10.96 (0.26, 21.65), .04 |
Pre- 1 year | 157 (32) | -53 (62%) | -51 (67%) | -2 (-16.15, 12.15), .78 |
Pre- 2 years | 257,58 (69)b | -42.06 (54%) | -61.20 (74%) | 10.87 (-20.54, 42.3), .49 |
P det at Qmax (cm H 2 O) | ||||
Pre- 6 months | 158 (37) | -22.52 (35%) | -40 (53%) | 17.48 (13.8, 21.2), .00 |
Pre- 2 years | 158(37) | -28.56 (44%) | -35 (47%) | 6.44 (2.32, 10.56), .00 |
Variable | No. studies (patients) | TUNA Difference in means (% improvement) | VLAP Difference in means (% improvement) | TUNA vs. VLAP WMD (95% CI), P value |
Symptom score | ||||
Pre- 6 months | 157 (30) | -9 (47%) | -7.3 (37%) | -1.7 (-4.0,0.62), .15 |
Pre-1 year | 157 (30) | -11.2 (58%) | -10.8 (55%) | -0.4 (-2.48, 1.68), .70 |
Pre- 2 years | 157 (30) | -10 (52%) | -12.9 (65%) | 2.9 (1.3, 4.5), .00 |
Qmax (mL/s) | ||||
Pre- 6 months | 157 (30) | 4.3 (41%) | 8.6 (141%) | -4.3 (-6.17, -2.43),.00 |
Pre- 1 year | 157 (30) | 2.6 (30%) | 7.8 (128%) | -5.2 (-6.3, -3.57), .00 |
Pre- 2 years | 157 (30) | 2.3 (44%) | 5.6 (92%) | -3.3 (-4.7, -1.8), .00 |
PVR (mL) | ||||
Pre- 6 months | 157 (30) | -44 (62%) | -63 (67%) | 19 (1.90, 36.1), .02 |
Pre- 1 year | 157 (30) | -53 (62%) | -64 (68%) | 11 (-6.44, 28.44), .2 |
Pre- 2 years | 157 (30) | -55 (54%) | -68 (72%) | 13 (-5.6, 31.6), .17 |
Variable | No. studies (patients) | TUNA Difference in means (% improvement) | HIFU Difference in means (% improvement) | TUNA vs. HIFU WMD (95% CI), P value |
Symptom score | ||||
Pre- 6 months | 157 (35) | -9 (47%) | -8.3 (56%) | -0.7 (-2.35, 0.95), .40 |
Pre- 1 year | 157 (35) | -11.2 (58%) | -10.4 (71%) | -0.8 (-2.11, 0.51), .23 |
Pre- 2 years | 157 (35) | -10 (52%) | -7 (48%) | -3.0 (-4.71, -1.29), .00 |
Qmax (mL/s) | ||||
Pre- 6 months | 157 (35) | 4.3 (41%) | 3.9 (42%) | 0.40 (-9.4, 1.74), .55 |
Pre- 1 year | 157 (35) | 2.6 (30%) | 3.9 (42%) | -1.30 (-2.16, -0.44), .00 |
Pre- 2 years | 157 (35) | 2.3 (44%) | 2 (22%) | 0.30 (-0.52, 1.12), .47 |
PVR (mL) | ||||
Pre- 6 months | 157 (35) | -44 (62%) | -48 (51%) | 4.00(-10.44, 18.44), .58 |
Pre- 1 years | 157 (35) | -53 (62%) | -45 (48%) | -8.00 (-22.44, 6.44), .27 |
Pre- 2 years | 157 (35) | -55 (54%) | -36 (38%) | -19 (33.69, -4.31), .01 |